ACADL

Across TCGA pan-cancer cohorts, ACADL RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of ACADL’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ACADL RNA is repressed in tumor relative to normal tissue. In most cancer types ACADL is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

HNSC, LUAD, and STAD are the cancer types where ACADL tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACADL RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	All	−0.774	<.001	12	view →
LUAD	Female	III,IV	−3.963	<.001	11	view →
STAD	Male	III,IV	−0.626	<.001	10	view →
LUSC	Female	II,III,IV	−3.702	<.001	9	view →
THCA	All	II,III,IV	−0.939	<.001	9	view →
LIHC	Female	II,III,IV	−2.239	<.001	8	view →
BRCA	All	III,IV	−2.190	<.001	8	view →
COAD	All	II,III,IV	−0.135	<.001	6	view →
CHOL	All	All	−2.737	<.001	3	view →
BLCA	Male	IV	−0.547	.011	3	view →
READ	All	All	−0.355	.001	3	view →
KIRC	Female	All	+0.731	.027	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

ACADL–HNSC

Open the HNSC breakdown →